Safety and efficacy in presbyopic patients with flexivue microlens

Session Details

Session Title: Intracorneal Inlays for Presbyopia

Session Date/Time: Tuesday 08/09/2015 | 16:00-18:00

Paper Time: 16:24

Venue: Main Auditorium

First Author: : V.Feingold USA

Co Author(s): :                        

Abstract Details

Purpose:

To evaluate the safety and efficacy of Flexivue Microlens in prebyopic patients using retrospective multicenters analysis.

Setting:

Multicenter study in clinics located in Greece, Czech Republic and Ireland

Methods:

A retrospective Study of 193 patients aged 40 to 65, 104 males and 88 females who were evaluated with contact lens for tolerance to Mono vision were implanted with Flexivue Microlens (Presbia, Netherlands) at 300 microns in a stroma pocket created by femtosecond laser. The patients underwent visual acuity evaluations for near and distance vision using EDTRS charts. Manifest refraction were taken and compared to the actual lens power that was implanted. The followup was for 6 months.

Results:

The patients' average microlens power that implanted was 2.26 D with std deviation of 0.41. After surgery the average refraction in the operated eye for distance was -1.76 D with std deviation of 1.45 D, while for near it was -.01 D with std deviation of 0.65 D. The average uncorrected near visual acuity of the operated eye before surgery was LogMAR 0.76 and improved to LogMAR of 0.18. The average binocular uncorrected visual acuity before surgery was LogMAR 0.07 and improved to LogMAR-0.02 after surgery. 1.5% of patients experienced minor haze. Most patients achieved resolution with topical steroid regimen. 1.3% of patients underwent inlay explantation. No reduction in endothelial cells count were observed.

Conclusions:

The method of implanting a corneal inlay (Presbia Flexivue Microlens) is effective in reducing dependence on glasses in presbyopic patient. No severe safety issue were reported.

Financial Interest:

One of the authors gains financially from product or procedure presented, One of the authors travel has been funded, fully or partially, by a competing company, One of the authors has significant investment interest in a competing company